...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Nephrology >Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study
【24h】

Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study

机译：羧麦芽糖铁对非透析慢性肾脏病患者血清磷酸盐和C端FGF23水平的影响：一项前瞻性研究的事后分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Some parenteral iron therapies have been found to be associated with hypophosphatemia. The mechanism of the decrease in serum phosphate is unknown. The aim of this study is to examine the effect of IV ferric carboxymaltose(FCM) on phosphate metabolism and FGF23 levels in patients with chronic kidney disease(CKD). Methods This is a post-hoc analysis of a prospective study carried out in 47 non-dialysis CKD patients with iron-deficiency anaemia who received a single 1000?mg injection of FCM. Markers of mineral metabolism (calcium, phosphate, 1,25-dihydroxyvitamin D, PTH and FGF23[c-terminal]) were measured prior to FCM administration and at week 3 and week 12 after FCM administration. Based on the measured levels of serum phosphate at week 3, patiens were classified as hypophosphatemic or non-hypophosphatemic. Results Serum phosphate levels decreased significantly three weeks after FCM administration and remained at lower levels at week 12 (4.24?±?0.84 vs 3.69?±?1.10 vs 3.83?±?0.68?mg/dL, respectively, p? Conclusions In non-dialysis CKD patients, FCM induces reduction in serum phosphate levels that persists for three months. FCM causes a significant decrease in FGF23 levels without changes to other bone metabolism parameters.
机译：背景技术已经发现一些肠胃外铁疗法与低磷血症有关。血清磷酸盐减少的机制尚不清楚。这项研究的目的是检查慢性肾脏病（CKD）患者中静脉注射羧甲基麦芽糖铁（FCM）对磷酸盐代谢和FGF23水平的影响。方法这是一项针对前瞻性研究的事后分析，该研究针对47名非透析性CKD缺铁性贫血患者进行了一次1000 mg的FCM注射。在给予FCM之前以及给予FCM后的第3周和第12周，测量了矿物质代谢的指标（钙，磷酸盐，1,25-二羟基维生素D，PTH和FGF23 [c-末端]）。根据第3周测得的血清磷酸盐水平，将患者分为低磷酸盐血症或非低磷酸盐血症。结果FCM给药三周后血清磷酸盐水平显着下降，并在第12周保持较低水平（分别为4.24±±0.84 vs 3.69±±1.10 vs 3.83±±0.68μg/ dL，p？结论）透析CKD患者，FCM导致血清磷酸盐水平降低，持续3个月; FCM导致FGF23水平显着降低，而其他骨骼代谢参数没有变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号